Navigation Links
SkyePharma and Sciele Pharma Announce Successful Completion of New,Sular Formulation Clinical Trial Programme

.

Certain statements in this news release are forward-looking statements and are made in reliance on the safe harbour provisions of the U.S. Private Securities Litigation Act of 1995. Although SkyePharma believes that the expectations reflected in these forward-looking statements are reasonable, it can give no assurance that these expectations will materialize. Because the expectations are subject to risks and uncertainties, actual results may vary significantly from those expressed or implied by the forward-looking statements based upon a number of factors, which are described in SkyePharma's 20-F and other documents on file with the SEC. Factors that could cause differences between actual results and those implied by the forward-looking statements contained in this news release include, without limitation, risks related to the development of new products, risks related to obtaining and maintaining regulatory approval for existing, new or expanded indications of existing and new products, risks related to SkyePharma's ability to manufacture products on a large scale or at all, risks related to SkyePharma's and its marketing partners' ability to market products on a large scale to maintain or expand market share in the face of changes in customer requirements, competition and technological change, risks related to regulatory compliance, the risk of product liability claims, risks related to the ownership and use of intellectual property, and risks related to SkyePharma's ability to manage growth. SkyePharma undertakes no obligation to revise or update any such forward-looking statement to reflect events or circumstances after the date of this release.



'"/>




Page: 1 2 3

Related medicine technology :

1. Sciele Pharma Announces Successful Completion of New Sular Formulation Clinical Trial Program
2. Sygnis Pharma AG announces date for presentation of clinical results
3. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
4. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
6. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
7. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
8. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
9. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
10. Array BioPharma to Present at the C.E Unterbeg, Towbin Emerging Growth Conference
11. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
Post Your Comments:
(Date:10/20/2014)... 2014 Norgine B.V. today announced ... volume bowel preparation, NER1006, presented at the 79 th ... Gastroenterology (ACG), Philadelphia, PA , has ... and co-primary endpoint of cleansing success. The study demonstrated ... ® in screening colonoscopy patients. [1] ...
(Date:10/19/2014)... -- Henry Schein, Inc. (NASDAQ: HSIC ), the ... to office-based dental, animal health and medical practitioners, announced ... Inc., a leading full-service provider of dental consumables, implants ... into Japan , the world,s 2 ... the number of countries in which the Company operates. ...
(Date:10/17/2014)... , Oct. 17, 2014  Training market researchers ... critical success factor in today,s highly competitive global ... research organizations that effectively and efficiently produce high ... service area. Effective training programs ... earn recognition from internal clients by developing analysts ...
Breaking Medicine Technology:Positive Results from Phase II Data Show NER1006 Achieves High Quality Bowel Cleansing Efficacy 2Henry Schein Enters Japan With Investment in Iwase Dental Supply 2Henry Schein Enters Japan With Investment in Iwase Dental Supply 3Henry Schein Enters Japan With Investment in Iwase Dental Supply 4Henry Schein Enters Japan With Investment in Iwase Dental Supply 5Effective Training Programs for Market Research Groups can Boost Overall Organizational Success 2
... , MALVERN, ... a privately held biopharmaceutical company, and Cephalon, Inc. (Nasdaq: ... trial for CINQUIL(TM) (reslizumab) as a treatment for pediatric eosinophilic ... in the co-primary endpoints of changes in esophageal eosinophil levels ...
... , WAPPINGERS ... Medical, in alliance with the American Academy of Pediatrics (AAP), ... with Laerdal,s SimNewB (TM) neonatal patient simulator. SimNewB is designed ... to facilitate training for treatment of other critical medical conditions ...
Cached Medicine Technology:Ception Therapeutics and Cephalon Provide Initial Results of a Phase IIb/III Study of CINQUIL in Pediatric Eosinophilic Esophagitis 2Ception Therapeutics and Cephalon Provide Initial Results of a Phase IIb/III Study of CINQUIL in Pediatric Eosinophilic Esophagitis 3Ception Therapeutics and Cephalon Provide Initial Results of a Phase IIb/III Study of CINQUIL in Pediatric Eosinophilic Esophagitis 4Ception Therapeutics and Cephalon Provide Initial Results of a Phase IIb/III Study of CINQUIL in Pediatric Eosinophilic Esophagitis 5Neonatal Scenarios Developed in Partnership with the American Academy of Pediatrics (AAP), Utilize the NRP Curriculum to Advance Newborn Care 2Neonatal Scenarios Developed in Partnership with the American Academy of Pediatrics (AAP), Utilize the NRP Curriculum to Advance Newborn Care 3
(Date:10/20/2014)... 20, 2014 AttorneyOne.com, a recognized authority on ... from the FDA on Sit and Slim II . ... to purchase or use Sit and Slim II because it ... is promoted as weight loss product on various websites and ... market in 2010 for safety reasons, can significantly increase blood ...
(Date:10/20/2014)... October 20, 2014 Rockynol Retirement ... Center on Oct. 14. The $11 million project will ... and a cooked-to-order kitchen with full-service restaurant style dining. ... choice for first class Assisted Living apartments,” said Kara ... deserve the highest quality of care and this investment ...
(Date:10/20/2014)... (PRWEB) October 20, 2014 Based ... are the only imaging assays capable of determining ... single test.  With these three dimensions of high-resolution ... to detect the widest range of disease-causing genetic ... missed by other genomic tools, including today’s advanced ...
(Date:10/20/2014)... Final Cut Pro X Plugin developers from Pixel ... for FCPX filmmakers . , “Fun, cool, and simple ... theme” Says Christina Austin, CEO of Pixel Film Studios. “It ... Citrus comes with all the tools needed for a ... for added style, a title screen for an introduction, two ...
(Date:10/20/2014)... 2014 It’s hard to imagine what it’s ... vulnerable children around the world, it’s a reality. And while ... children are forced to walk barefoot on rocky terrain or ... play with their friends. , Buckner International's Shoes ... Radio in October to encourage support for Air1 and ...
Breaking Medicine News(10 mins):Health News:FDA Advises Not to Use Sit and Slim II: AttorneyOne Monitors and Keeps Consumers Informed 2Health News:Rockynol Retirement Community Expands Assisted Living Center 2Health News:KromaTiD Launches Genome Screening and Discovery Services 2Health News:KromaTiD Launches Genome Screening and Discovery Services 3Health News:Today Pixel Film Studios Announced the Release of the Citrus theme for Final Cut Pro X 2Health News:Buckner Shoes for Orphan Souls® Garners Support from Air1 Radio 2Health News:Buckner Shoes for Orphan Souls® Garners Support from Air1 Radio 3
... Paragon Medsystems unveiled their new corporate identity at ... Effective immediately, the company name will be California MedTech.The ... providing turnkey development and manufacturing services to the medical ... focus on the medtech sector, as well as our ...
... Hepatocellular carcinoma (HCC) is a highly aggressive form of ... cancers worldwide. Devanand Sarkar and colleagues, at Virginia Commonwealth ... gene that is expressed at high levels in human ... HCC progression. They therefore suggest that targeting this gene ...
... the two might be genetic, researchers say , , MONDAY, Feb. ... melanoma are twice as likely to develop Parkinson,s disease, a ... are not clear, other studies have shown that people with ... "For people with a family member with melanoma, they may ...
... patients who undergo surgery at teaching-intensive hospitals have ... these better survival rates apparently occur in white ... in surgical outcomes for patients in teaching-intensive hospitals ... from other studies," said study leader Jeffrey H. ...
... improved expertise after surgery, but reasons unclear, study finds ... are less likely to die of post-surgery complications at ... doesn,t apply to black patients, a U.S. study. finds. ... at The Children,s Hospital of Philadelphia and the University ...
... technological breakthroughsCLEVELAND, Feb. 16 NorTech, in partnership ... to announce the winners of its annual Innovation ... Northeast Ohio innovators who are impacting the lives ... world. This year, a distinguished panel of judges ...
Cached Medicine News:Health News:Paragon Medsystems Becomes California MedTech 2Health News:Family History of Melanoma Doubles Parkinson's Risk 2Health News:White Patients Benefit More Than Blacks in Surviving Surgical Complications at Teaching Hospitals 2Health News:White Patients Benefit More Than Blacks in Surviving Surgical Complications at Teaching Hospitals 3Health News:Teaching Hospitals' Post-Op Gains Not Extended to Blacks 2Health News:NorTech, Crain's Cleveland Business Honor 2009 Innovation Award Winners 2Health News:NorTech, Crain's Cleveland Business Honor 2009 Innovation Award Winners 3Health News:NorTech, Crain's Cleveland Business Honor 2009 Innovation Award Winners 4Health News:NorTech, Crain's Cleveland Business Honor 2009 Innovation Award Winners 5
... Portex® Blue Line ULTRA® Suctionaid® tracheostomy tubes ... removal of secretions from above the tracheostomy ... ULTRA® Suctionaid® tracheostomy tubes provide an additional ... from above the tracheostomy tube cuff helping ...
Manufactured form the same soft siliconized PVC as all Portex® Blue Line® tracheostomy tubes....
... For additional patient safety, ... with an integral 15 mm ... connected to a ventilator, with ... in place , ,Portex® ...
... When the all silicone cuff ... no distinguishable dimension to the ... shaft, yet it can be ... varied airway management needs. TTS™ ...
Medicine Products: